Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rocheste...
Saved in:
Main Authors: | Timothy L Comstock, Paul M Karpecki, Timothy W Morris, et al |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/558707f1c679417aa2490cd37df17be9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
by: Silverstein BE, et al.
Published: (2012) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
by: Morris TW, et al.
Published: (2011) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
by: Haas W, et al.
Published: (2011) -
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
by: Bucci FA Jr, et al.
Published: (2015) -
Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
by: Gail Torkildsen, et al.
Published: (2010)